Advancing Laboratory Sustainability: My Green Lab Launches Certification 2.0
SAN DIEGO, January 30, 2025 /3BL/ - My Green Lab, the global nonprofit organization advancing the sustainability of laboratory research, is proud to announce the launch of My Green Lab® Certification 2.0. This enhanced certification program sets a new standard for sustainability in science, featuring advanced tools and resources designed to drive measurable environmental and financial impact in laboratories worldwide. Updates to the program include third-party verification, streamlined engagement surveys, and an integrated Impact Estimator tool.
Recognized by the United Nations Race to Zero campaign as a key measure for progress toward a zero-carbon future, and recommended by the U.S. EPA, My Green Lab Certification is the world's most trusted green lab certification. The latest updates strengthen the program's impact while enhancing its rigor, integrity, and scalability.
Key features of My Green Lab Certification 2.0 include:
AstraZeneca was the first organization to implement the enhanced program in October 2024, setting the stage for widespread adoption of My Green Lab Certification 2.0. With today's official launch, My Green Lab Certification 2.0 is now ready to deliver measurable environmental and financial outcomes across the scientific community.
'The enhancements to our certification program reflect My Green Lab's commitment to continuous improvement and our dedication to empowering labs to lead the charge in environmental sustainability,' said James Connelly, CEO of My Green Lab. 'With My Green Lab Certification 2.0, we're equipping labs with actionable insights within a user-friendly and powerful platform for driving meaningful change.'
About My Green Lab
My Green Lab® is a nonprofit environmental organization with a mission to build a global culture of sustainability in science. The organization is the world leader in developing internationally recognized sustainability standards for laboratories and laboratory products—bringing sustainability to the community responsible for the world's life-changing medical and technical innovations. Laboratories are some of the most resource-intensive spaces in any industry, but they don't have to be. By introducing a new perspective and proven best practices within a carefully crafted framework, My Green Lab has inspired tens of thousands of scientists and lab professionals to make positive changes in their labs by reducing the environmental impact of their work.
My Green Lab Certification
The world's most trusted green lab certification, guiding scientists and lab teams toward actionable sustainability practices. Supported by third-party verification from Impact Laboratories, My Green Lab Certification has engaged 3,800 labs in 50 countries reaching over 41,000 scientists (as of early 2025).
For media requests, contact Christina Creager at [email protected].
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
MetaMelt Announces Official Website Update Featuring Enhanced User Interface and Access to Metabolic Wellness Resources
SHERIDAN, June 09, 2025 (GLOBE NEWSWIRE) — MetaMelt, a U.S.-based wellness brand developed by Aspen Brass LLC, has launched a newly enhanced version of its official website, featuring updated tools, improved navigation, and expanded access to product information and wellness resources. The update is designed to streamline the user experience and provide clearer, faster access to educational content and purchasing options. According to the company, the redesigned interface improves site performance across desktop and mobile devices. Visitors to the site can now benefit from a simplified homepage layout, improved internal search functionality, and faster page loading times. The update also includes a more intuitive navigation bar and a reorganized FAQ section to help users find answers quickly. 'We're excited to offer our visitors a more intuitive, seamless experience as they explore the MetaMelt brand,' said a company spokesperson. 'This website upgrade reflects our ongoing commitment to transparency, accessibility, and customer support.' In addition to a new layout and backend performance improvements, the website update includes refreshed product descriptions, policy disclosures, and a streamlined checkout process. These changes were made in response to customer feedback and the growing demand for wellness brands that offer both convenience and clarity online. The company reports that its customer support section now features updated contact tools and a clearer breakdown of service hours. Website visitors can access all support channels directly through the footer menu or mobile navigation, along with links to expanded educational content and order tracking tools. About MetaMelt MetaMelt is a wellness brand developed by Aspen Brass LLC, focused on creating natural, easy-to-use supplements that support everyday health and metabolic balance. With a commitment to transparency and simplicity, the company strives to provide effective, quality-driven solutions to help adults feel their best. Product and Contact Information Brand: MetaMelt Website: Email: [email protected] Phone: 855-210-1448 Mailing Address: Aspen Brass LLC, 1309 Coffeen Ave Ste 17470, Sheridan, WY 82801 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
5 hours ago
- Yahoo
World's First Needle-Free Procedure Targeting Deep Facial Muscles and Skin, EMFACE® by BTL Aesthetics Surpasses 1 Million Global Treatments, Drives Rapid Adoption in Singapore's Aesthetic Market
SINGAPORE, June 10, 2025 /PRNewswire/ -- EMFACE® the groundbreaking non-invasive natural facial lifting treatment developed by BTL Aesthetics (BTL), has surpassed 1 million treatments worldwide within the first two years of its introduction. This global milestone is a testament to EMFACE®'s position as the leading non-invasive aesthetic treatment, leveraging breakthrough technology to invent the first needle-free procedure capable of effectively providing deep facial muscle toning and skin tightening for a more lifted and youthful appearance. Launched in the United States in 2022 and introduced to Singapore in March 2023, the award- winning EMFACE® quickly gained traction among aesthetic practitioners and patients seeking effective non-invasive facial rejuvenation in major markets such as the United States, Europe, Singapore, Japan, Korea and Taiwan. According to various doctors, the demand for non-invasive aesthetic treatments in Singapore continues to rise due to reduced stigma as aesthetic treatments are increasingly viewed as a form of self-care, as reported by Channel News Asia[1]. Additionally, The Straits Times[2] has also highlighted that advancements in technology are providing more convenient solutions with minimal downtime, allowing for more accessible and efficient treatments. "In recent years, we have seen a major shift in what patients are looking for – effective treatments that deliver natural-looking results without needles, surgery, or extended recovery times. Today's consumers are busy and want options that fit seamlessly into their lifestyles, and non-invasive treatments are answering that call," said Dr. Lynn Chiam, Dermatologist at the Children & Adult Skin Hair Laser Clinic. Channel News Asia[1] has also noted that The Ministry of Health (MOH) reported an average increase of 40 new licensed providers offering aesthetic services between 2020 and 2023. As more individuals seek effective and non-invasive options to achieve their desired appearance, this surge reflects the increasing preference for non-invasive treatments like EMFACE®, with demand expected to grow even further. To cater to the growing demand for non-invasive aesthetic treatments, EMFACE® effectively targets the facial elevator muscles for a natural lift in just 20 minutes, with no pain and no downtime. Although tangible results can be seen right after the treatments, a minimum of four sessions can deliver truly optimal results. Additionally, a fully personalized treatment plan can be curated by trusted Aesthetic Providers. EMFACE® is the first device in the market to utilise High-intensity Facial Electrical Stimulation (HIFES) and Synchronized RF technologies. HIFES™ selectively tones the face-elevating muscles to restore and elevate the support of facial features while Synchronized RF heating remodels and smooths the skin by increasing the levels of collagen and elastin fibers. This allows the treatment to penetrate deep into the facial muscles, lifting every layer from muscle to skin, effectively enhancing facial contours from within – a feat previously unattainable with injectables or traditional energy-based devices. EMFACE® has also expanded its capabilities with the introduction of under-eye applicators, making EMFACE® the only treatment available that addresses the root causes of ageing around the eyes non-invasively by toning muscles and tightening skin. The periorbital area is often the first to show signs of ageing with eyebags, crow's feet, and dark circles. While traditional solutions focus primarily on the skin, the new eye applicators further enhance the treatment's effectiveness by uniquely targeting both the lower part of the orbicularis oculi muscle and delicate skin in the periorbital area. As the original muscle toning and skin lifting U.S. FDA-cleared treatment, EMFACE® has been recognized for its innovative technology and revolutionary results, having won the 2025 New Beauty Award for 'Best Non-Invasive Facial Sculptor', the 2023 Northern Ireland Cosmetic Medicine Award for 'Innovative Device of the Year', and the 2023 Cosmopolitan Holy Grail Beauty Award for 'Best Treatment Game Changer'. "BTL Aesthetics is proud of reaching this remarkable milestone which underscores the commitment we have to providing cutting-edge innovative aesthetic solutions. Achieving 1 million EMFACE® treatments globally in under two years highlights the growing consumer demand for non-invasive facial lifting solutions that are painless, require no downtime, and can seamlessly fit into their busy routines," said Mr Ricardo Manaloto, General Manager of BTL Aesthetics. "We are truly heartened by the trust that our valued partner practitioners have placed in EMFACE®. Their recognition of the role that toning facial muscles plays in facial lifting reinforces its importance as a foundational component of any effective facial lifting treatment. Mr. Manaloto added. For more information about EMFACE® and the available trusted providers in Singapore, visit BTL Aesthetics Singapore at [1] Channel News Asia – Youths, seniors embracing aesthetics boom: up/youths-seniors-embracing-aesthetics-boom-4635091 [2] The Straits Times – Social media influencers driving demand for aesthetic treatments in Singapore: About BTL Aesthetics Founded in 1993, BTL has grown to become one of the world's leading medical equipment manufacturers. With 500+ engineers and 3,000+ employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including intimate health and mental wellness. Among other brands, BTL's products include EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, EXOMIND™ as well as their proprietary HIFEM®, HIFES™ and EXOTMS™ procedures. View original content: SOURCE BTL Singapore Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care
PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the leader in non-invasive liver diagnostics, and Boehringer Ingelheim, a global biopharmaceutical company, today announced an expansion of their long-standing partnership to change the trajectory of the disease by moving beyond clinical trials to focus on early detection, diagnosis, and access to care. By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next phase of partnership will include: Raising awareness of MASH among patients, healthcare professionals, and policymakers about the urgent need for early screening and diagnosis. Encouraging the adoption of streamlined care pathways by fostering collaboration across healthcare organizations and medical specialties. Expanding awareness and access to non-invasive technologies (NITs), including scientific collaborations to generate evidence relating to NITs in the care of people living with MASH. "For too long, serious liver diseases like MASH have gone under the radar—but with MASH rates soaring alongside the global obesity epidemic, it's time to tackle liver disease head on," said Sandy Sommer, Head of the Therapeutic Area for Cardiovascular, Renal and Metabolic at Boehringer Ingelheim. "Obesity and MASH are deeply interconnected chronic diseases that no organization can tackle alone. At Boehringer, we're committed to being part of the solution, and the expansion of our partnership with Echosens is one we're particularly excited about. We look forward to working together to drive transformative change in metabolic health for patients, doctors, and healthcare systems worldwide." MASH is a chronic disease that results from excess fat accumulation and inflammation in the liver. It is more common in people living with obesity and, left untreated, can lead to scarring, cirrhosis, and liver failure. Because the disease is often silent in its early stages, it is estimated that fewer than one in five people with MASH are formally diagnosed, underscoring the urgent need for scalable and non-invasive tools to screen these patients and support them with ongoing care. FibroScan®, Echosens' non-invasive liver assessment technology, has played a critical role in Boehringer Ingelheim's liver disease research and continues to support two ongoing Survodutide Phase III trials by screening and monitoring patients; as a non-invasive test, FibroScan® offers a fast, painless, cost-effective, and scalable alternative to liver biopsy. Survodutide combines GLP-1 and glucagon receptor agonists as a novel potential treatment for MASH and associated metabolic conditions like obesity. Survodutide is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal and metabolic disease areas. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. "We are excited to expand our collaboration with Boehringer Ingelheim, whose innovative approach has the potential to further advance the treatment landscape for MASH," said Dominique Legros, CEO of Echosens. "This partnership reflects our ongoing commitment to support the global liver disease community by enabling smarter clinical trials and broader access to non-invasive diagnostic tools. We are proud to collaborate with Boehringer Ingelheim and welcome them into our shared mission to improve liver health outcomes." About Echosens Pioneer in its field, Echosens, significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 5,384 peer-reviewed publications and 218 international guidelines. Echosens has made FibroScan® available in over 127 countries, enabling millions of liver examinations worldwide. About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. View original content: SOURCE Echosens Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
